HomeClinical Evidence LibraryMold & Mycotoxin Toxicity
Toxicology

Mold toxicity is a vascular and inflammatory disease

Mycotoxins cause endothelial damage, systemic inflammation, and impaired lymphatic drainage. EECP improves circulation, reduces inflammatory markers, and supports the body's detoxification pathways.

↓Inflammation
Systemic inflammatory markers (CRP, IL-6) reduce after EECP
↑Lymph
Improved lymphatic circulation supports mycotoxin clearance
↑Perfusion
Better tissue perfusion supports organ detoxification
Non-toxic
No additional chemical burden — purely mechanical treatment
Mechanism of Action

How EECP works for Mold & Mycotoxin Toxicity

STEP 01
Diastolic augmentation

Cuffs inflate in diastole, driving a wave of blood retrograde through the aorta — increasing coronary perfusion pressure and delivering oxygen-rich blood to ischemic tissue.

STEP 02
Nitric oxide release

Increased shear stress on the endothelium triggers release of nitric oxide — the body's master vasodilator — improving vessel tone and reducing inflammation.

STEP 03
Angiogenesis

Repeated sessions stimulate VEGF and other growth factors, promoting the formation of new collateral blood vessels in ischemic tissue.

STEP 04
Systemic vascular improvement

Endothelial function improves throughout the body — not just at the heart — producing benefits in peripheral, cerebral, and microvascular circulation.

Find a provider who treats Mold & Mycotoxin Toxicity
Search 139 verified EECP centers — filter by condition and location.
Research & Articles

Clinical evidence and patient resources

Click any headline to read the full article. New research and patient stories are added regularly.

Peer-Reviewed Research

Related Studies

3 studies

Peer-reviewed studies, RCTs, and meta-analyses from the EECP clinical evidence library relevant to Mold Illness / CIRS. Click any title to access the source.

RCT
Enhanced External Counterpulsation Reduces Inflammatory Cytokines in Coronary Artery Disease (Sham-RCT) ↗

Casey DP, Beck DT, Braith RW · Journal of Applied Physiology (PMC) · 2008

Review
Consensus
Dr. Buscher MD Clinical Protocol: EECP for Mycotoxin Toxicity ↗

Buscher D, MD · Clinical Practice Protocol (BuscherMD.com) · 2023

View all research studies in the library →
Medical Disclaimer: The information on this page summarizes published clinical research and is provided for educational purposes only. It is not intended as medical advice and should not replace consultation with a qualified healthcare provider. EECP is FDA-cleared for specific cardiac indications; use for other conditions is off-label and should be discussed with your physician.
← Back to Clinical Evidence Library